Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, V. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Henderson, V. W.
NEUROLOGY 1997;48:27S-35S
© 1997 American Academy of Neurology

The epidemiology of estrogen replacement therapy and Alzheimer's disease

Victor W. Henderson, MD

From the Departments of Neurology (Division of Cognitive Neuroscience and Neurogerontology) and Psychology, School of Gerontology, and Program in Neural, Informational, and Behavioral Sciences, University of Southern California, and the Los Angeles County-University of Southern California Medical Center, Los Angeles, CA.
Supported in part by NIH grants AG05142 and AG06790 and by the Thomas and Mary Bowles Fund.
Presented in part at the 10th World Congress of Psychiatry, Madrid, Spain, August 23, 1996.
Address correspondence and reprint requests to Dr. Victor W. Henderson, Department of Neurology (GNH-5641), University of Southern California School of Medicine, 1200 North State Street, Los Angeles, CA 90033-1084.

Abstract.

Article abstract-The burden of Alzheimer's disease (AD) falls more heavily on women than men. It is hypothesized that plummeting levels of circulating estrogens after the menopause increase a woman's risk for this disorder and, conversely, that estrogen replacement therapy may lower the risk for dementia due to AD. A number of estrogenic properties support the biological credibility of this hypothesis. Estrogen interacts with neurotrophins and neurotransmitter systems relevant to AD and in some model systems estrogen modulates synaptic plasticity. Effects on beta-amyloid and apolipoprotein E may be especially germane to putative protective effects. Estrogen also may blunt neurotoxic consequences of the stress response mediated by the hypothalamic-pituitary-adrenal axis, augment cerebral glucose utilization, and enhance cerebral blood flow. Clinical studies of postmenopausal women suggest beneficial estrogen effects on specific cognitive skills, and small preliminary trials of estrogen replacement in women with AD support claims of clinically meaningful efficacy. Consistent with the estrogen hypothesis, cross-sectional studies imply that postmenopausal estrogen use could be associated with a lower risk for AD. Several recent epidemiologic studies in which information on estrogen replacement therapy was collected prospectively further support this contention, with a dose-response relation evident in some reports. Because estrogen users tend to differ from nonusers in a number of lifestyle characteristics, convincing demonstration of putative protective effects could best come from randomized, placebo-controlled, primary intervention trials. For the present, however, the issue of estrogen efficacy in lowering a woman's risk for AD remains unsettled.

NEUROLOGY 1997;48(Suppl 7): S27-S35






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by AAN Enterprises, Inc.